USD 1.27
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| FATE | 1.6 | -12.4 | -23.5 | -60.7 | -70.3 | -72.0 | -96.8 | -94.8 | -73.6 | -80.8 |
| S&P 500 | 1.0 | 3.7 | 2.2 | 2.3 | 8.9 | 23.9 | 32.3 | 80.6 | 196.5 | 33856.2 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | FATE |
| name | Fate Therapeutics, Inc. |
| price | 1.27 |
| changes percentage | 1.6 |
| change | 0.02 |
| day low | 1.24 |
| day high | 1.3 |
| year high | 8.83 |
| year low | 1.04 |
| market cap | 144645380 |
| price avg 50 | 2.1038 |
| price avg 200 | 3.4723 |
| exchange | NASDAQ |
| volume | 1267939 |
| avg volume | 3239242 |
| open | 1.28 |
| previous close | 1.25 |
| eps | -1.64 |
| pe | -0.77 |
| earnings announcement | 2025-02-24T10:59:00.000+0000 |
| shares outstanding | 113894000 |
| timestamp | 2025-01-17 21:00:01 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001434316 | |||
| revenue | 63533000 | 96300000 | -34.03 |
| gross profit | -98163000 | 82542000 | -218.92 |
| gross profit ratio | -1.55 | 0.86 | -280.26 |
| research and development expenses | 172596000 | 320454000 | -46.14 |
| operating expenses | 254044000 | 404686000 | -37.22 |
| interest income | 17186000 | 5842000 | 194.18 |
| interest expense | 0 | 5842000 | -100.00 |
| ebitda | -172229000 | -294628000 | 41.54 |
| ebitdaratio | -2.71 | -3.2 | 15.35 |
| operating income | -190511000 | -308386000 | 38.22 |
| operating income ratio | -3.0 | -3.2 | 6.36 |
| net income | -160928000 | -255056000 | 36.90 |
| net income ratio | -2.53 | -2.65 | 4.36 |
| eps | -1.64 | -2.63 | 37.64 |
Revenue Growth: revenue decreased to 64 million in 2023 from 96 million in 2022 representing a change of -34.03%. This indicates a sales shrinking, which is a negative sign for the company.
Gross Profit: Gross Profit decreased to -98 million in 2023 from 83 million in 2022 representing a change of -218.92%. This indicates a sales profitability decline, which is a negative sign for the company.
Research and Development (R&D) Expenses: R&D Expenses decreased to 173 million in 2023 from 320 million in 2022 representing a change of -46.14%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -172 million in 2023 from -295 million in 2022 representing a change of 41.54%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Operating Income: Operating income decreased to -191 million in 2023 from -308 million in 2022 representing a change of 38.22%. The decrease in operating income indicates worse operational performance and decreased profitability.
Net Income: Net income decreased to -161 million in 2023 from -255 million in 2022 representing a change of 36.9%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
Operating Expenses: Operating Expenses decreased to 254 million in 2023 from 405 million in 2022 representing a change of -37.22%. The decrease in operating expenses can be attributed to various factors such as improved profitability, cost optimization and financial stability, lower operating expenses can be positive indicators.
Earnings per Share (EPS): EPS increased to -1.64 in 2023 from -1.64 in 2022 representing a change of 37.64%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001434316 | |||
| revenue | 3074000 | 6772000 | -54.61 |
| gross profit | 3074000 | -27832000 | 111.04 |
| gross profit ratio | 1 | -4.11 | 124.33 |
| research and development expenses | 34650000 | 34604000 | 0.13 |
| operating expenses | 55451000 | 51855000 | 6.93 |
| interest income | 4438000 | 4827000 | -8.06 |
| interest expense | 0 | 0 | NaN |
| ebitda | -52377000 | -40362000 | -29.77 |
| ebitdaratio | -17.04 | -5.96 | -185.88 |
| operating income | -52377000 | -45083000 | -16.18 |
| operating income ratio | -17.04 | -6.66 | -155.94 |
| net income | -47678000 | -38427000 | -24.07 |
| net income ratio | -15.51 | -5.67 | -173.33 |
| eps | -0.4 | -0.33 | -21.21 |
Revenue Growth: revenue decreased to 3 million in 2024Q3 from 7 million in 2024Q2 representing a change of -54.61%. This indicates a sales shrinking, which is a negative sign for the company.
Operating Expenses: Operating Expenses increased to 55 million in 2024Q3 from 52 million in 2024Q2 representing a change of 6.93%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
Earnings per Share (EPS): EPS increased to -0.4 in 2024Q3 from -0.4 in 2024Q2 representing a change of -21.21%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
Gross Profit: Gross Profit increased to 3 million in 2024Q3 from -28 million in 2024Q2 representing a change of 111.04%. This indicates a sales profitability growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 35 million in 2024Q3 from 35 million in 2024Q2 representing a change of 0.13%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -52 million in 2024Q3 from -40 million in 2024Q2 representing a change of -29.77%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -52 million in 2024Q3 from -45 million in 2024Q2 representing a change of -16.18%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -48 million in 2024Q3 from -38 million in 2024Q2 representing a change of -24.07%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001434316 | |||
| total assets | 506217000 | 705561000 | -28.25 |
| total liabilities | 137800000 | 221622000 | -37.82 |
| total equity | 368417000 | 483939000 | -23.87 |
| cash and cash equivalents | 41870000 | 61333000 | -31.73 |
| short term investments | 273305000 | 374894000 | -27.10 |
| long term investments | 980000 | 4942000 | -80.17 |
| total current assets | 331540000 | 502074000 | -33.97 |
| total non current assets | 174677000 | 203487000 | -14.16 |
| total current liabilities | 39094000 | 114051000 | -65.72 |
| total non current liabilities | 98706000 | 107571000 | -8.24 |
| common stock | 99000 | 97000 | 2.06 |
| retained earnings | -1211732000 | -1050804000 | -15.31 |
| total debt | 103536000 | 109338000 | -5.31 |
Total Assets: Total Assets decreased to 506 million in 2023 from 706 million in 2022 representing a change of -28.25%. Suggesting a decrease in asset holdings.
Total Equity: Total Equity decreased to 368 million in 2023 from 484 million in 2022 representing a change of -23.87%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 42 million in 2023 from 61 million in 2022 representing a change of -31.73%. This indicates a decrease in available liquid assets.
Short Term Investments: Short Term Investments decreased to 273 million in 2023 from 375 million in 2022 representing a change of -27.1%. This indicates a decrease in short-term investment holdings.
Total Current Assets: Total Current Assets decreased to 332 million in 2023 from 502 million in 2022 representing a change of -33.97%. This indicates a worsen liquidity position.
Retained Earnings: Retained Earnings decreased to -1,212 million in 2023 from -1,051 million in 2022 representing a change of -15.31%. This indicates an accumulated losses.
Total Liabilities: Total Liabilities decreased to 138 million in 2023 from 222 million in 2022 representing a change of -37.82%. This indicates a decrease in overall liabilities.
Total Current Liabilities: Total Current Liabilities decreased to 39 million in 2023 from 114 million in 2022 representing a change of -65.72%. This indicates a lower short-term debt burden.
Common Stock: Common Stock increased to 0 in 2023 from 0 in 2022 representing a change of 2.06%. This indicates an increase in ownership interest.
Total Debt: Total Debt decreased to 104 million in 2023 from 109 million in 2022 representing a change of -5.31%. This indicates a reduction in overall debt burden.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001434316 | |||
| total assets | 494970000 | 528817000 | -6.40 |
| total liabilities | 132644000 | 131835000 | 0.61 |
| total equity | 362326000 | 396982000 | -8.73 |
| cash and cash equivalents | 37909000 | 36917000 | 2.69 |
| short term investments | 259014000 | 267962000 | -3.34 |
| long term investments | 33607000 | 47162000 | -28.74 |
| total current assets | 310294000 | 319388000 | -2.85 |
| total non current assets | 184676000 | 209429000 | -11.82 |
| total current liabilities | 37422000 | 34793000 | 7.56 |
| total non current liabilities | 95222000 | 97042000 | -1.88 |
| common stock | 114000 | 114000 | 0.00 |
| retained earnings | -1345841000 | -1298163000 | -3.67 |
| total debt | 98978000 | 100562000 | -1.58 |
Total Assets: Total Assets decreased to 495 million in 2024Q3 from 529 million in 2024Q2 representing a change of -6.4%. Suggesting a decrease in asset holdings.
Total Liabilities: Total Liabilities increased to 133 million in 2024Q3 from 132 million in 2024Q2 representing a change of 0.61%. This indicates an increase in overall liabilities.
Total Equity: Total Equity decreased to 362 million in 2024Q3 from 397 million in 2024Q2 representing a change of -8.73%. This indicates a decrease in shareholders' equity.
Short Term Investments: Short Term Investments decreased to 259 million in 2024Q3 from 268 million in 2024Q2 representing a change of -3.34%. This indicates a decrease in short-term investment holdings.
Total Current Assets: Total Current Assets decreased to 310 million in 2024Q3 from 319 million in 2024Q2 representing a change of -2.85%. This indicates a worsen liquidity position.
Total Current Liabilities: Total Current Liabilities increased to 37 million in 2024Q3 from 35 million in 2024Q2 representing a change of 7.56%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -1,346 million in 2024Q3 from -1,298 million in 2024Q2 representing a change of -3.67%. This indicates an accumulated losses.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 38 million in 2024Q3 from 37 million in 2024Q2 representing a change of 2.69%. This indicates an increase in available liquid assets.
Total Debt: Total Debt decreased to 99 million in 2024Q3 from 101 million in 2024Q2 representing a change of -1.58%. This indicates a reduction in overall debt burden.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001434316 | |||
| net change in cash | -19513000 | -72250000 | 72.99 |
| operating cash flow | -132263000 | -248208000 | 46.71 |
| free cash flow | -138416000 | -283774000 | 51.22 |
| capital expenditure | -6153000 | -35566000 | 82.70 |
| depreciation and amortization | 18282000 | 13758000 | 32.88 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 43459000 | 78733000 | -44.80 |
| accounts payables | -28940000 | 14252000 | -303.06 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | -202317000 | 100.00 |
| investments in property plant and equipment | -6153000 | -35566000 | 82.70 |
| net cash used for investing activites | 112665000 | 166751000 | -32.44 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 85000 | 9207000 | -99.08 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 85000 | 9207000 | -99.08 |
| cash at end of period | 57047000 | 76560000 | -25.49 |
| accounts receivables | 36654000 | -29804000 | 222.98 |
| cash at beginning of period | 76560000 | 148810000 | -48.55 |
Net Change in Cash: Net Change in Cash increased to -20 million in 2023 from -72 million in 2022 representing a change of 72.99%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to -132 million in 2023 from -248 million in 2022 representing a change of 46.71%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to -138 million in 2023 from -284 million in 2022 representing a change of 51.22%. This indicates an increase in cash generated after accounting for capital expenditures.
Stock-Based Compensation: Stock-Based Compensation decreased to 43 million in 2023 from 79 million in 2022 representing a change of -44.8%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Capital Expenditure: Capital Expenditure increased to -6 million in 2023 from -36 million in 2022 representing a change of 82.7%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Accounts Payables: The absolute value of Accounts Payables increased to 29 million in 2023 from 14 million in 2022 representing a change of -303.06%. This indicates that the company has increased its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables increased to 37 in 2023 from -30 million in 2022 representing a change of 222.98%. This suggests that the company is less capable of collecting payments from its customers.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001434316 | |||
| operating cash flow | -29419000 | -32305999 | 8.94 |
| free cash flow | -29914000 | -32357000 | 7.55 |
| capital expenditure | -495000 | -51000 | -870.59 |
| depreciation and amortization | -2943000 | 4721000 | -162.34 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 11765000 | 9630000 | 22.17 |
| accounts receivables | -2479000 | -190000 | -1204.74 |
| accounts payables | 1871000 | 320000 | 484.69 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -495000 | -51000 | -870.59 |
| net cash used for investing activites | 25461000 | -53373000 | 147.70 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | -94527000 | -662000 | -14179.00 |
| common stock repurchased | 666000 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 0 | 1274000 | -100.00 |
| net change in cash | -3958000 | -84405000 | 95.31 |
| cash at end of period | 48136000 | 36917000 | 30.39 |
| cash at beginning of period | 52094000 | 121322000 | -57.06 |
Net Change in Cash: Net Change in Cash increased to -4 million in 2024Q3 from -84 million in 2024Q2 representing a change of 95.31%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to -29 million in 2024Q3 from -32 million in 2024Q2 representing a change of 8.94%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to -30 million in 2024Q3 from -32 million in 2024Q2 representing a change of 7.55%. This indicates an increase in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure decreased to 0 million in 2024Q3 from 0 million in 2024Q2 representing a change of -870.59%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Accounts Receivables: Accounts Receivables decreased to -2 million in 2024Q3 from 0 million in 2024Q2 representing a change of -1204.74%. This suggests that the company has been able to collect payments from its customers more efficiently and timely.
Stock-Based Compensation: Stock-Based Compensation increased to 12 million in 2024Q3 from 10 million in 2024Q2 representing a change of 22.17%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables increased to 2 million in 2024Q3 from 0 million in 2024Q2 representing a change of 484.69%. This indicates that the company has increased its outstanding obligations to its suppliers.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q1 2024 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 0.65 | 0.99 | -35.09 |
| net income per share | -1.64 | -2.63 | 37.92 |
| operating cash flow per share | -1.34 | -2.56 | 47.57 |
| free cash flow per share | -1.41 | -2.93 | 52.01 |
| cash per share | 3.2 | 4.51 | -28.91 |
| book value per share | 3.74 | 5.0 | -25.10 |
| tangible book value per share | 3.74 | 5.0 | -25.10 |
| shareholders equity per share | 3.74 | 5.0 | -25.10 |
| interest debt per share | 1.05 | 1.19 | -11.56 |
| market cap | 368057745.88 | 976974925.22 | -62.33 |
| enterprise value | 429723745.88 | 1024979925.22 | -58.07 |
| pe ratio | -2.29 | -3.83 | 40.29 |
| price to sales ratio | 5.79 | 10.15 | -42.90 |
| pocfratio | -2.78 | -3.94 | 29.30 |
| pfcf ratio | -2.66 | -3.44 | 22.76 |
| pb ratio | 1.0 | 2.02 | -50.51 |
| ptb ratio | 1.0 | 2.02 | -50.51 |
| ev to sales | 6.76 | 10.64 | -36.45 |
| enterprise value over ebitda | -2.5 | -3.48 | 28.28 |
| ev to operating cash flow | -3.25 | -4.13 | 21.32 |
| ev to free cash flow | -3.1 | -3.61 | 14.05 |
| earnings yield | -0.44 | -0.26 | -67.48 |
| free cash flow yield | -0.38 | -0.29 | -29.47 |
| debt to equity | 0.28 | 0.23 | 24.39 |
| debt to assets | 0.2 | 0.15 | 31.98 |
| net debt to ebitda | -0.36 | -0.16 | -119.75 |
| current ratio | 8.48 | 4.4 | 92.64 |
| interest coverage | 0 | -52.79 | 100.00 |
| income quality | 0.82 | 0.88 | -6.72 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 1.25 | 0.87 | 42.97 |
| research and ddevelopement to revenue | 2.72 | 3.33 | -18.36 |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | -0.05 | -0.14 | 67.53 |
| capex to revenue | 0.1 | 0.37 | -73.78 |
| capex to depreciation | 0.34 | 2.59 | -86.98 |
| stock based compensation to revenue | 0.68 | 0.82 | -16.33 |
| graham number | 11.74 | 17.21 | -31.81 |
| roic | -0.4 | -0.46 | 13.10 |
| return on tangible assets | -0.32 | -0.36 | 12.06 |
| graham net net | 1.82 | 2.51 | -27.77 |
| working capital | 292446000 | 388023000 | -24.63 |
| tangible asset value | 368417000 | 483939000 | -23.87 |
| net current asset value | 193740000 | 280452000 | -30.92 |
| invested capital | 450957000 | 454092000 | -0.69 |
| average receivables | 20153000 | 23578000 | -14.53 |
| average payables | 6492000 | 8438500 | -23.07 |
| average inventory | 0.5 | 0.5 | 0.00 |
| days sales outstanding | 10.49 | 145.85 | -92.81 |
| days payables outstanding | 10.65 | 219.27 | -95.14 |
| days of inventory on hand | 0 | 0.0 | -100.00 |
| receivables turnover | 34.79 | 2.5 | 1290.30 |
| payables turnover | 34.26 | 1.66 | 1958.43 |
| inventory turnover | 0 | 13758000 | -100.00 |
| roe | -0.44 | -0.53 | 17.12 |
| capex per share | 0.06 | 0.37 | -82.98 |
ROE: Return on Equity (ROE) increased to -0.44 on 2023-12-31 from -0.53 on 2022-12-31, representing a change of 17.12%. However, ROE is <= 5%, suggesting that the company has not been generating high returns for its shareholders.
Current Ratio: Current Ratio increased to 8.48 on 2023-12-31 from 4.40 on 2022-12-31, representing a change of 92.64%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -2.29 on 2023-12-31 from -3.83 on 2022-12-31, representing a change of 40.29%. Indicating an increase in the relative valuation of the company's stock.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.28 on 2023-12-31 from 0.23 on 2022-12-31, representing a change of 24.39%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| FATE | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 0.03 | 0.06 | -54.72 |
| net income per share | -0.4 | -0.33 | -23.76 |
| operating cash flow per share | -0.25 | -0.28 | 9.17 |
| free cash flow per share | -0.25 | -0.28 | 7.79 |
| cash per share | 2.52 | 2.6 | -2.86 |
| book value per share | 3.08 | 3.38 | -8.96 |
| tangible book value per share | 3.08 | 3.38 | -8.96 |
| shareholders equity per share | 3.08 | 3.38 | -8.96 |
| interest debt per share | 0.84 | 0.86 | -1.83 |
| market cap | 412192063.5 | 382946084.24 | 7.64 |
| enterprise value | 473261063.5 | 446591084.24 | 5.97 |
| pe ratio | -2.16 | -2.49 | 13.25 |
| price to sales ratio | 134.09 | 56.55 | 137.12 |
| pocfratio | -14.01 | -11.85 | -18.20 |
| pfcf ratio | -13.78 | -11.84 | -16.43 |
| pb ratio | 1.14 | 0.96 | 17.93 |
| ptb ratio | 1.14 | 0.96 | 17.93 |
| ev to sales | 153.96 | 65.95 | 133.46 |
| enterprise value over ebitda | -9.04 | -11.06 | 18.34 |
| ev to operating cash flow | -16.09 | -13.82 | -16.37 |
| ev to free cash flow | -15.82 | -13.8 | -14.63 |
| earnings yield | -0.12 | -0.1 | -15.27 |
| free cash flow yield | -0.07 | -0.08 | 14.11 |
| debt to equity | 0.27 | 0.25 | 7.84 |
| debt to assets | 0.2 | 0.19 | 5.16 |
| net debt to ebitda | -1.17 | -1.58 | 26.06 |
| current ratio | 8.29 | 9.18 | -9.67 |
| interest coverage | 0 | 0 | NaN |
| income quality | 0.62 | 0.84 | -26.61 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 6.77 | 2.55 | 165.63 |
| research and ddevelopement to revenue | 11.27 | 5.11 | 120.59 |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | -0.02 | -0.0 | -965.84 |
| capex to revenue | 0.16 | 0.01 | 2038.20 |
| capex to depreciation | -0.17 | 0.01 | -1656.96 |
| stock based compensation to revenue | 3.83 | 1.42 | 169.14 |
| graham number | 5.29 | 4.99 | 6.14 |
| roic | -0.11 | -0.09 | -26.90 |
| return on tangible assets | -0.1 | -0.07 | -32.56 |
| graham net net | 1.42 | 1.43 | -0.60 |
| working capital | 272872000 | 284595000 | -4.12 |
| tangible asset value | 362326000 | 396982000 | -8.73 |
| net current asset value | 177650000 | 187553000 | -5.28 |
| invested capital | 413705000 | 431676000 | -4.16 |
| average receivables | 2587500 | 1403000 | 84.43 |
| average payables | 5922000 | 6130000 | -3.39 |
| average inventory | -5880500 | -5880500 | 0.00 |
| days sales outstanding | 120.83 | 13.93 | 767.53 |
| days payables outstanding | 0 | 14.29 | -100.00 |
| days of inventory on hand | 0 | -30.59 | 100.00 |
| receivables turnover | 0.74 | 6.46 | -88.47 |
| payables turnover | 0 | 6.3 | -100.00 |
| inventory turnover | 0 | -2.94 | 100.00 |
| roe | -0.13 | -0.1 | -35.94 |
| capex per share | 0.0 | 0.0 | 868.11 |
ROE: Return on Equity (ROE) decreased to -0.13 on 2024-09-30 Q3 from -0.10 on 2024-06-30 Q2, representing a change of -35.94%. Suggesting that the company has not been generating high returns for its shareholders.
Current Ratio: Current Ratio decreased to 8.29 on 2024-09-30 Q3 from 9.18 on 2024-06-30 Q2, representing a change of -9.67%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -2.16 on 2024-09-30 Q3 from -2.49 on 2024-06-30 Q2, representing a change of 13.25%. Indicating an increase in the relative valuation of the company's stock.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.27 on 2024-09-30 Q3 from 0.25 on 2024-06-30 Q2, representing a change of 7.84%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
None
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2025-01-03 16:01:00
SAN DIEGO, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on January 2, 2025 the Company granted (i) non-qualified stock options to two newly-hired non-executive employees to purchase a total of 72,000 shares of the Company's common stock at an exercise price per share of $1.79, which was the closing price per share of the Company's common stock as reported by NASDAQ on January 2, 2025, the options grant date, and (ii) restricted stock units (RSUs) representing 3,200 shares of its common stock to one newly-hired non-executive employee. The grants were approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years, with 25% of the shares underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% vesting in approximately equal monthly installments over the following thirty-six months, subject to the employees being continuously employed by the Company through each vesting date. The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employee being continuously employed by the Company through each vesting date.
Sentiment: Neutral
Publish Date: 2024-12-12 12:36:29
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock?
Sentiment: Positive
Publish Date: 2024-12-09 16:01:00
All Three Patients Treated in First Dose Cohort Administered Fludarabine-free Conditioning and Show Rapid, Deep, and Sustained B-cell Depletion with Favorable Safety Profile
Sentiment: Positive
Publish Date: 2024-12-03 16:01:00
SAN DIEGO, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on December 2, 2024 the Company granted restricted stock units (RSUs) representing 18,600 shares of its common stock to one newly-hired non-executive employee. The grant was approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employee being continuously employed by the Company through each vesting date.
Sentiment: Positive
Publish Date: 2024-11-29 13:05:00
Bob Valamehr, Ph.D. MBA, To Become President and CEO January 1, 2025 Scott Wolchko To Retire as President and CEO after 10 years of Leadership in Pioneering iPSC-derived Cellular Immunotherapies SAN DIEGO, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE) (“Fate Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company dedicated to bringing first-in-class induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that Scott Wolchko, the Company's President and CEO, will retire effective December 31, 2024.
Sentiment: Negative
Publish Date: 2024-11-26 16:01:00
SAN DIEGO, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that the Company will participate in the following upcoming investor conferences:
Sentiment: Positive
Publish Date: 2024-11-20 16:34:16
Fate Therapeutics, Inc. reported positive phase 1 data for FT819 in treating moderate-to-severe Systemic Lupus Erythematosus, showing remission in one patient with fludarabine-free conditioning. A second study arm will test FT819 as an add-on to maintenance therapy without conditioning chemotherapy targeting SLE patients. Data from the first three patients will be presented at the American Society of Hematology Annual Meeting, being held between December 7th through 10th of 2024.
Sentiment: Positive
Publish Date: 2024-11-19 14:55:34
Fate Therapeutics presents promising data on FT819 showing the first patient treated experienced a favorable clinical experience, achieved drug-free clinical remission, and continues on-study.
Sentiment: Positive
Publish Date: 2024-11-18 08:05:00
27-year-old African American-Asian Woman with Active Lupus Nephritis Achieved DORIS Clinical Remission; Patient Remains On-study, in Clinical Remission, and Free of All Immunosuppressive Therapies
Sentiment: Positive
Publish Date: 2024-11-13 12:21:14
FATE reports a narrower-than-expected loss on higher revenues for the third quarter of 2024. The company's innovative pipeline is in focus.
Sentiment: Negative
Publish Date: 2024-11-12 18:21:15
Fate Therapeutics (FATE) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $0.46 per share a year ago.
Sentiment: Neutral
Publish Date: 2024-11-12 16:01:00
Initial Clinical Data from Phase 1 Autoimmunity Study of FT819 1XX CAR T-cell Product Candidate to be Presented in 4Q24; Second Treatment Arm Adding FT819 to Maintenance Therapy without Conditioning Chemotherapy Opened for Enrollment
Sentiment: Positive
Publish Date: 2024-11-09 13:30:00
Novel H 2 CasMab-2 Antigen Binding Domain Shown to Preferentially Target HER2 Expressed on Tumor Cells in Preclinical Studies
Sentiment: Negative
Publish Date: 2024-11-08 16:01:00
Multiplexed-engineered, iPSC-derived CAR T Cell Targets Proteins Expressed on Cancer Cells in Response to Cellular Stress and Malignant Transformation
Sentiment: Positive
Publish Date: 2024-11-04 16:01:00
SAN DIEGO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on November 1, 2024 the Company granted restricted stock units (RSUs) representing 20,000 shares of its common stock to one newly-hired non-executive employee. The grant was approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employee being continuously employed by the Company through each vesting date.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
